#68 UPDATE: A Leftist Primer to the Right-Wing Psychedelic Takeover
Release Date: 04/24/2026
The Psymposia Podcast
Russell, Normie, Pace and James debut a new podcast format covering the latest developments in psychedelics, drug policy, and politics. Today, they review the latest Church of Sacred Synthesis lawsuit news, misperceptions of the "psychedelic Left", Purdue Pharma’s collapse, the Trump administration's cuts to fentanyl test strip funding, vaccine and ivermectin discourse, and worsening conditions in veterans’ mental healthcare. Footnotes: Michelle Lhooq — “We Have Entered the Era of Conservative Psychedelia” Associated Press — “OxyContin maker Purdue Pharma to dissolve...
info_outlineThe Psymposia Podcast
Psymposia board member Dr. Neşe Devenot’s presentation at the Ohio State University “Religion and Psychedelics” conference, recorded March 28, 2026. In this talk, Dr. Devenot presents their research on the reliance on unscientific telepathic attunement in many popular schools of psychedelic therapy.
info_outlineThe Psymposia Podcast
Professor Dave is a well-known science communicator and prolific debunker of pseudoscience. Despite building his platform on combatting misinformation, he continues joining conversations that promote false claims about the FDA’s rejection of MDMA-assisted therapy — one of which he republished on his own channel. In this episode, Psymposia responds to the latest of these conversations on the Danny Jones Podcast. We encourage Professor Dave to do his homework on the psychedelic industry before aligning himself with the very pseudoscience promoters he's built his career opposing.
info_outlineThe Psymposia Podcast
Three psychedelic companies received vouchers for expedited FDA review: Usona, Compass Pathways, and Otsuka—NOT Resilient Pharmaceuticals. This voucher announcement is yet another vindication of our reporting on major problems and pseudoscience within Lykos’/Resilient's trials. Update to episode #68.
info_outlineThe Psymposia Podcast
Psychedelics are the next front in Big Tech's dystopia. Psymposia developed this primer for leftists in response to Donald Trump‘s April 18 Executive Order, which accelerates review of psychedelic drugs deemed “Breakthrough Therapies” and makes Schedule 1 drugs more accessible under Right to Try laws. This announcement made a splash in psychedelic media, where praise for the Trump administration mixes with false claims about an “end to prohibition.” In this discussion, we provide important context about this Executive Order and the people who engineered this moment behind the scenes....
info_outlineThe Psymposia Podcast
It has become a problematic standard practice in the psychedelic therapy industry to increase drug dosages after patients display red flag symptoms. Psymposia discusses a recent Wall Street Journal article about these practices as they manifest in the ketamine industry; the psychedelic industry’s historic normalization of these practices; and recent attempts to convince lawmakers to protect psychedelic providers from liability for standard forms of medical malpractice. Together, these developments highlight why allowing a therapy cult to influence the norms of psychedelic medicine puts the...
info_outlineThe Psymposia Podcast
In this final episode, we explore the attempts made by Hamilton Morris to attack the work, integrity, and character of our team.
info_outlineThe Psymposia Podcast
Psymposia discusses Hamilton Morris's misinformation about their funding, his relationship with Compass Pathways, his claims that the nonprofit Usona has planted protestors at conferences to make him look bad, and claims that Psymposia encouraged terrorism.
info_outlineThe Psymposia Podcast
Psymposia discusses their history with the Church of Psilomethoxin and addresses Hamilton Morris's misinformation about their funding and the alleged elder abuse of psychedelic funder George Sarlo by MAPS Board Chair Vicky Dulai.
info_outlineThe Psymposia Podcast
Psymposia addresses Hamilton Morris's misinformation, including his speculation that they are DEA informants, their behavior at the FDA advisory committee for Lykos' Therapeutics' MDMA application, and more.
info_outlineThree psychedelic companies received vouchers for expedited FDA review: Usona, Compass Pathways, and Otsuka—NOT Resilient Pharmaceuticals. This voucher announcement is yet another vindication of our reporting on major problems and pseudoscience within Lykos’/Resilient's trials. Update to episode #68.